ArticleBMC cancer2026
Transrectal ultrasound-guided optimization of needle insertion for interstitial brachytherapy in the treatment of vaginal stump recurrence of cervical cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical value of real‑time transrectal ultrasound (TRUS) guidance in interstitial brachytherapy (ISBT) for patients with vaginal stump recurrence after hysterectomy for cervical cancer.
methodsThis retrospective, non-randomized study included 32 patients receiving ISBT who were categorized into two groups: Group A (TRUS‑guided ISBT, n=16) and Group B (non‑TRUS‑guided ISBT, n=16). A total of 39 procedures were performed in Group A, involving 137 implanted interstitial needles, while Group B underwent 37 procedures with 145 needles implanted. Postoperative computed tomography (CT) was used to evaluate vaginal stump unintended perforation rates, penetration depth, and rectal or bladder perforation.
resultsA total of 282 interstitial needles were implanted across both groups.The vaginal stump unintended perforation rate in Group A was significantly lower than in Group B (16.06% vs. 40.69%, P < 0.05). Furthermore, In Group A, 22 (22/137) needles perforated the vaginal stump, with a mean penetration depth of 3.36 ± 1.32 mm, while in Group B, 59 (59/145) needles perforated the vaginal stump, with a mean penetration depth of 5.29 ± 3.51 mm; The mean penetration depth in Group A was significantly lower than that in Group B (t = -3.576; P < 0.05). Additionally, the incidence of rectal and bladder perforation was significantly lower in Group A compared to Group B (2.92% vs. 12.41%, P < 0.05).
conclusionThe use of TRUS guidance in ISBT for vaginal stump recurrence significantly reduces the incidence and depth of unintended perforations and is anticipated to lower the risk of fistula formation. These findings support TRUS as a promising technique for enhancing the safety of ISBT in patients with recurrent cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.